Physician profile
Alya D Torna
NPI 1306051024
$1,176.23
in general payments reported to CMS, 2019-2025
18 companies · $37.07 in 2025
The $37.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $405 · 2021: $259 · 2023: $144 · 2024: $163 · 2025: $37.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $138.44 | 2019-2021 | |
| Amarin Pharma, INC. | $129.99 | 2020-2021 | |
| Horizon Therapeutics Plc | $125.43 | 2023 | Tepezza |
| Dexcom, INC. | $120.00 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.70 | 2019-2021 | |
| Mannkind Corporation | $94.33 | 2020-2021 | |
| Lilly USA, LLC | $92.39 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $75.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $59.98 | 2020 | |
| Novo Nordisk INC | $46.33 | 2019-2024 | |
| Amgen INC. | $44.50 | 2024-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $37.43 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $25.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.98 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.89 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.72 | 2021 | |
| Abbvie INC. | $15.40 | 2020 | |
| Intra-Sana Laboratories | $15.24 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alya Torna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.